PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11144721

[Recent immunologic aspects].

M Pastural·P Lang
View original source ↗Export metadata ↓

Abstract

Three main aspects of rejection are described in kidney transplantation: hyperacute graft rejection mediated by cytotoxic antibodies, acute rejection initiated by lymphocytes T CD4+ activated after direct or indirect pathways of allopeptides recognition, and chronic rejection (graft chronic dysfunction). Immunologic and non-immunologic factors have been implicated in the development of chronic rejection but there is no evidence for a unique physiopathological pathway. The various steps of immune response in acute rejection have been better defined in the past years. The development of new immunosuppressive drugs and their combination have led to drastic decrease of acute graft rejection occurrence. On the other hand, highly HLA sensitized recipients, chronic graft rejection and toxicity of immunosuppressive drugs should support active research but the final goal is the induction of a specific tolerance.

Explore related subjects

Graft RejectionHistocompatibility TestingHumansImmunosuppressive AgentsIsoantibodiesKidney TransplantationRenal InsufficiencyT-LymphocytesTransplantation ToleranceEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Pastural, P Lang. 2000. [Recent immunologic aspects].. https://pubmed.ncbi.nlm.nih.gov/11144721/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Hypoimmune platforms: from rejection to immune evasion and regulatory implications.

The growing gap between organ demand and clinical availability has renewed interest in immune-evasive graft strategies, yet rejection and lifelong immunosuppression remain major barriers to durable success. Advances in genome editing enable immune-evasive cell platforms designed to avoid immune recognition while replacing missing function in allogeneic settings. This review summarizes current strategies for engineering immune-evasive grafts that simultaneously suppress adaptive and innate immune responses. We discuss how coordinated modulation of antigen presentation and immune checkpoint pathways can protect transplanted allogeneic cells and tissues from T, NK, and macrophage-mediated rejection. We also present the emerging concept of integrating hypoimmune engineering with genetically modified porcine donors, where extensive genome editing has reduced, but not eliminated, xenogeneic immune barriers. Combining donor genome modification with immune-evasive graft design represents a promising conceptual advance toward xenograft survival, though whether full elimination of systemic immunosuppression is achievable remains to be established clinically. We further examine how the regulatory landscape for these products is evolving across major jurisdictions, and how differences in approval pathways, manufacturing standards, and long-term surveillance requirements shape the path to clinical translation. Finally, we outline the safety considerations and remaining limitations in immune evasion that must be addressed to enable clinical implementation.

Graft Rejection↗
PubMed2001

Hyperlipidemia and cardiovascular disease after organ transplantation.

Hyperlipidemia, a frequent and persistent complication after solid organ transplantation, contributes to cardiovascular morbidity and mortality and may influence the development of allograft vasculopathy. The pathogenesis of posttransplantation hyperlipidemia is not fully understood, although several epidemiological factors are strongly implicated including age, weight, pretransplantation lipid levels, and immunosuppressive therapy. Management strategies to reduce hyperlipidemia and modify cardiovascular risk include dietary restrictions and the use of lipid-lowering agents. The selective use of immunosuppressants, such as tacrolimus, that have neutral or fewer adverse effects on lipid metabolism may also provide a useful option. A combination of lipid-lowering therapies and optimization of immunosuppressive regimens compatible with prolonged allograft survival is probably necessary to significantly reduce posttransplantation hyperlipidemia and its potentially harmful consequences.

Graft Rejection↗